Expense analysts at HC Wainwright initiated coverage on shares of Acumen Prescribed drugs (NASDAQ:ABOS – Get Ranking) in a research note issued to buyers on Thursday, MarketBeat reviews. The brokerage established a “buy” ranking and a $15.00 selling price target on the stock. HC Wainwright’s target price indicates a probable upside of 218.47% from the company’s earlier near.
Separately, Credit rating Suisse Team diminished their concentrate on rate on shares of Acumen Prescription drugs from $26.00 to $17.00 and set an “outperform” score for the business in a investigate report on Tuesday, March 29th. Five analysts have rated the inventory with a buy ranking, In accordance to MarketBeat, the inventory currently has an average rating of “Buy” and a consensus value concentrate on of $20.00.
Shares of NASDAQ:ABOS opened at $4.71 on Thursday. Acumen Prescribed drugs has a fifty-two 7 days low of $3.02 and a fifty-two week substantial of $20.99. The firm has a 50-working day very simple going ordinary of $3.70 and a 200 working day straightforward relocating ordinary of $4.81.
A selection of institutional investors have recently added to or lessened their stakes in ABOS. Geode Capital Management LLC obtained a new placement in Acumen Prescription drugs in the 3rd quarter valued at somewhere around $1,601,000. Janus Henderson Group PLC acquired a new placement in Acumen Pharmaceuticals in the 3rd quarter valued at roughly $12,773,000. Strs Ohio increased its stake in shares of Acumen Prescribed drugs by 1,413.6% throughout the 4th quarter. Strs Ohio now owns 33,300 shares of the company’s inventory worthy of $225,000 following purchasing an added 31,100 shares in the course of the very last quarter. New York Point out Prevalent Retirement Fund acquired a new placement in shares of Acumen Prescription drugs for the duration of the 4th quarter truly worth $37,000. Eventually, Northern Have faith in Corp amplified its stake in shares of Acumen Pharmaceuticals by 8.7% all through the 4th quarter. Northern Trust Corp now owns 94,984 shares of the company’s stock worthy of $642,000 just after purchasing an supplemental 7,583 shares all through the previous quarter. Hedge money and other institutional investors individual 64.42% of the company’s stock.
About Acumen Prescribed drugs (Get Ranking)
Acumen Prescription drugs, Inc, a medical-stage biopharmaceutical corporation, discovers and develops therapies for the treatment method of Alzheimer’s ailment. The company focuses on advancing a qualified immunotherapy drug applicant ACU193, a humanized monoclonal antibody that is in Period I scientific-stage to goal soluble amyloid-beta oligomers.
Receive News & Scores for Acumen Pharmaceuticals Day by day – Enter your email handle down below to obtain a concise every day summary of the latest news and analysts’ ratings for Acumen Prescription drugs and linked corporations with MarketBeat.com’s No cost day by day email newsletter.